Recon: FDA rejects Xspray’s Dasynoc over dosing and manufacturing concerns; EMA expands investigations into suicide risks of GLP-1 drugs
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy